Mycenax Biotech Inc.
4726
Rank in Stocks
#18079
Mycenax Biotech Inc. specializes in the research, development, and... Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the United States. The company cultivates a diverse portfolio of advanced biological therapeutics and components. This includes monoclonal antibodies, bi-specific antibodies, Fc-fusion proteins, recombinant proteins, peptides, non-toxic protein conjugates, antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), in addition to plasmids and DNA vaccines. Beyond product innovation, Mycenax offers a comprehensive suite of process development solutions. These encompass the establishment of production cell lines, optimization of upstream and downstream processes, industrial scale-up, formulation science, and the creation of analytical methods. The firm also provides in-house analytical testing, Good Manufacturing Practice (GMP)-compliant manufacturing services for drug substances and finished products, and cell banking, all underpinned by its specialized manufacturing technologies. Established in 2001, Mycenax Biotech Inc. is headquartered in Zhubei, Taiwan.
Share Price
$0.70114255
Last synced: 2026-11-10
Market Cap
$145.17M
Change (1 day)
9.79%
Change (1 year)
-34.64%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Mycenax Biotech Inc. (4726)
Category
Healthcare
EPS for Mycenax Biotech Inc. (4726)
EPS as of June 2026 TTM: $-0.06
According to Mycenax Biotech Inc.'s latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2025 the company had an EPS of $-0.07, equal to its 2024 EPS of $-0.07.
EPS history for Mycenax Biotech Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | -18.43% |
| 2025 | $-0.07 | 0.29% |
| 2024 | $-0.07 | -36.32% |
| 2023 | $-0.11 | 21.03% |
| 2022 | $-0.09 | 306.36% |
| 2021 | $-0.02 | -358.82% |
| 2020 | $0.01 | -114.60% |
| 2019 | $-0.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -27,525.57% |
US
|
|
| $-7.07 | 12,281.79% |
US
|
|
| $-5.29 | 9,164.45% |
AU
|
|
| $12.88 | -22,657.09% |
BE
|
|
| $21.56 | -37,858.32% |
NL
|
Questions about Mycenax Biotech Inc.'s earnings per share (EPS)
What is Mycenax Biotech Inc.'s earnings per share (EPS)?
Mycenax Biotech Inc.'s earnings per share (EPS) over the last twelve months is $-0.06, as of Jun 2026.
What was Mycenax Biotech Inc.'s earnings per share (EPS) in 2025?
In 2025, Mycenax Biotech Inc.'s earnings per share (EPS) was $-0.07, compared with $-0.07 in 2024.
How has Mycenax Biotech Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Mycenax Biotech Inc.'s earnings per share (EPS) was highest in 2020 ($0.01) and lowest in 2023 ($-0.11).
How does Mycenax Biotech Inc.'s earnings per share (EPS) compare with similar companies?
Mycenax Biotech Inc.'s earnings per share (EPS) ($-0.06) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.